Figures & data
Table 1. Epidemiological data to derive the eligible number of patients at each year of the analysis.
Table 2. Market shares in the scenario without and the scenario with iodixanol.
Table 3. Resource use in each country: mean values calculated from the results of experts’ interviews.
Table 4. Unit costs per country.
Table 5. Total and breakdown of cost (Euros) per CI-AKI hospitalization per patient in each country (local unit cost adjusted by resource use).
Table 6. Base case analysis results: impact on hospital budget following the introduction of iodixanol.
Table 7. Scenario analysis results: impact on hospital budget following the introduction of iodixanol, assuming emergency patients are included within the definition of CI-AKI increased risk.
Figure 1. Tornado diagrams presenting OWSA on the 3-years cumulative budget impact for the 10 most influent variables. Only eight variables are presented for Spain as all others did not have any impact on base case result.
